The treatments in the study are being performed using CLS’s TRANBERG®|Thermal Therapy System, optimized for high-precision thermal ablation treatment.
“The short term oncologic and functional outcomes for treatment of this group of patients is encouraging,” stated Dr. Sangeet Ghai, Vice Chief of Research and Abdominal Radiologist with the Toronto Joint Department of Medical Imaging (JDMI). “However, the long-term efficacy will be determined in the coming years.”

“It is very inspiring to see these first interim results from Dr. Sangeet Ghai’s work using our TRANBERG®|Thermal Therapy System. We look forward to continuing our collaboration through the outcome of this clinical study,” says Lars-Erik Eriksson, CEO at Clinical Laserthermia Systems.

“Dr. Ghai’s work provides valuable clinical data and extensive user experience from treating early stage prostate cancer with CLS TRANBERG-products and technology.”

Title: ”Early Oncological and Functional Outcomes following MR guided Focal Laser Ablation (MRgFLA)” 
BACKGROUND: Men diagnosed with localized low to intermediate risk prostate cancer and a significant life expectancy are usually offered the choice of two broad therapeutic options, either active treatment with surgery or irradiation with high risk of side effects.
Using its localizing strength, MRI has increased opportunities in the management of prostate cancer. Additionally, MR thermometry allows real time peri-procedural monitoring to ensure selective and adequate tumor ablation.
Focal therapy (FT) for prostate cancer (PCa) reduces functional complications with promising oncological results. Magnetic resonance image (MRI)-guided Focal Laser Ablation (MRgFLA) potentially maximizes precision. In this Phase II study, non water cooled 1064nm diode laser ­bers were used for ablation.
PURPOSE & AIM: This study aims to determine the oncologic and functional outcomes of MRgFLA in low-intermediate-risk localized PC in the single-center series of patients treated with the 1064nm diode laser fi­bers.
RESULTS: At the time of reporting, treatment was successfully completed in 21 patients. Intratreatment parameters are shown in Table 1. 14 patients with 15 lesions completed their 6 month follow up. No adverse events were reported.
CONCLUSION: MRgFLA shows encouraging short-term oncologic and functional outcomes for the treatment of low-intermediate-risk prostate cancer. However, the long-term efficacy will be determined in the coming years.
AUTHORS OF THE POSTER: Sangeet Ghai.1* Nathan Perlis,2 Masoom Haider,1 Guan Hee Tan,2 Kateri Corr,2 Rosanna Chan,1 Mark Gertner,1 Alex Zisman,2 Anna Konukhova,1 Sarah Jokhu,1 Theodorus van der Kwast,3 Stuart McCluskey,4 Antonio Finelli.2
1. Jt Dept of Medical Imaging, University Health Network – Mt Sinai Hospital, University of Toronto
2. Division of Urology, Dept of Surgical Oncology, University Health Network, University of Toronto
3. Laboratory Medicine Department, University Health Network, University of Toronto